Breaking Finance News

Illumina (NASDAQ:ILMN) has been upgraded from Mkt Perform to Outperform in a statement by Leerink Partners earlier today.

Having a price of $160.42, Illumina (NASDAQ:ILMN) traded 0.60% higher on the day. With the last stock price up 5.06% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. ILMN has recorded a 50-day average of $163.67 and a two hundred day average of $152.69. Trade Volume was up over the average, with 1,917,751 shares of ILMN changing hands over the typical 1,098,660

Leerink Partners has upgraded Illumina (NASDAQ:ILMN) from Mkt Perform to Outperform in a statement released on 03/20/2017.

On 3/20/2017, Vetr Inc. released a statement about Illumina (NASDAQ:ILMN) upped the target price from $0.00 to $187.82 that suggested an upside of 0.17%.

Recent Performance Chart

Illumina (NASDAQ:ILMN)

Illumina has PE ratio of 52.25 with a one year low of $119.37 and a one year high of $186.88 and has a market capitalization of $0.

A total of 19 brokerages have issued a ratings update on Illumina. Four brokerages rating the company a strong buy, four brokerages rating the company a buy, fifteen brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $154.53.

General Company Details For Illumina (NASDAQ:ILMN)

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.